DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations
Open Access
- 15 January 1991
- Vol. 67 (2) , 449-454
- https://doi.org/10.1002/1097-0142(19910115)67:2<449::aid-cncr2820670222>3.0.co;2-e
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myelomaBlood, 1988
- High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myelomaBlood, 1987
- The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosisBlood, 1985
- Prognostic implications of tumor cell DNA and RNA content in multiple myelomaBlood, 1985
- Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapyBritish Journal of Haematology, 1984
- Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patientsBlood, 1984
- Progress in the treatment of plasma cell myeloma?Journal of Clinical Oncology, 1983
- Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implicationsBlood, 1982
- The growth fraction of human myeloma cellsBlood, 1981
- Pretreatment tumor mass, cell kinetics, and prognosis in multiple myelomaBlood, 1980